Bolt Biotherapeutics Q2 2025 loss from ops $9.2M; cash $48.5M; BDC-4182 Phase 1 ongoing

Bolt Biotherapeutics, Inc.

2025-Q2 EPS reported -$10.22 vs consensus -$6.58 ▼ miss (-55.3%)

Collaboration revenue $1.8M (Q2 2024: $1.3M); R&D expenses down to $7.5M from $15.4M.
Loss from operations narrowed to $9.2M vs $22.6M year-over-year; restructuring charges zero vs $3.6M.
Cash, equivalents, and marketable securities $48.5M as of June 30, 2025; expected to fund operations through mid-2026.
Next-gen claudin 18.2 ISAC BDC-4182 Phase 1 dose-escalation open; initial data expected H1 2026.
Seeking partner for BDC-3042 after Phase 1 data; reverse stock split (1:20) done, regained Nasdaq compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.